Progesterone Receptor Negative Suspended Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Suspended2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03213041Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast CancerTreatment